Floatz logo

LANOLIN

Invasive Breast Carcinoma

City of Hope Medical CentermixturePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

41 Active assets in the Invasive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
TRASTUZUMAB
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

LANOLIN is also rated in:

Breast Ductal Carcinoma In SituDormant
CC
Indicative ·
43 / 100
View asset →
Breast CarcinomaDormant
D
Indicative ·
30 / 100
View asset →
Head and Neck CarcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →